Erythropoietin.
The remarkable capacity of the bone marrow to compensate for blood loss and for reduced atmospheric oxygen tension has been found to be mediated by a renal hormone, named erythropoietin. It is produced by peritubular interstitial cells in response to renal hypoxia, but molecular engineering has permitted large scale production of an identical recombinant erythropoietin in vitro. When used as a replacement hormone in patients with impaired endogenous production it has been found to be capable of improving or eliminating the anemia of chronic kidney disease and the anemia of prematurity. In the future it may also be used as a pharmacologic agent and possibly be able to control the anemia of patients with bone marrow failure and make them transfusion-independent.
Cardeza Foundation, Thomas Jefferson University, Philadelphia, PA 19107.
A J
AJ
Erslev
D000740:Anemia / Q000209:etiology / Q000628:therapy; D001853:Bone Marrow / Q000502:physiology; D004920:Erythropoiesis; D004921:Erythropoietin / Q000097:blood / Q000502:physiology* / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000150:complications; D011087:Polycythemia Vera / Q000175:diagnosis; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin